Investors Say Cancer Drug Co. Hyped Up Trial Results

Investors in a clinical-stage biopharmaceutical company have filed a proposed class action in Maryland federal court, accusing the drugmaker of falsely overstating the success of a breast cancer drug....

Already a subscriber? Click here to view full article